Back to Oncology
Oncologyv5.0Evidence-Based

Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic

Grades severity of hematologic and lymphatic adverse events from cancer treatment using standardized criteria. Assesses anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations.

Clinical Input Parameters

g/dL
Range: 0 — 25 g/dL
cells/mm³
Range: 0 — 50000 cells/mm³
cells/mm³
Range: 0 — 2000000 cells/mm³
cells/mm³
Range: 0 — 500000 cells/mm³
cells/mm³
Range: 0 — 50000 cells/mm³
°C
Range: 30 — 45 °C
Clinical Assessment
Awaiting Parameters
ctcae grade
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Grade assignment based on laboratory values compared to standardized thresholds for each adverse event type according to CTCAE v5.0 criteria

Clinical Pearls & Practice Notes

  • CTCAE v5.0 is the current standard for grading adverse events in cancer clinical trials
  • Normal ranges may vary by laboratory and patient population; use institutional standards when available
  • For febrile neutropenia, both neutropenia and fever criteria must be met
  • Grade 5 (death) requires clinical determination and cannot be assessed by laboratory values alone
  • Consider patient's baseline values and clinical condition when interpreting grades
  • This calculator focuses on common hematologic adverse events; full CTCAE includes hundreds of adverse event types

Evidence & Literature Citations

  1. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
  2. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021 Feb;112(2):90-92.
  3. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.

Score Interpretation Ranges

Grade 00 – 0 pts

Within normal limits

Grade 11 – 1 pts

Mild adverse event

Grade 22 – 2 pts

Moderate adverse event

Grade 33 – 3 pts

Severe adverse event

Grade 44 – 4 pts

Life-threatening adverse event

Grade 55 – 5 pts

Death

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.